Patient P-02142
Synthetic patientMETA-24 · Day 176 · 45–54 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
95%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 GI symptom burden −20% vs expected — Dietary Support Protocol NP-02
- Day 64 Tolerance state changed — Unstable → Improving
- Day 71 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 74 GI-04 recommended — GI Support Protocol GI-04
- Day 75 Patient accepted — Started GI-04 in the companion
- Day 83 GI symptom burden −34% vs expected — GI Support Protocol GI-04
- Day 89 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 71.
Primary contributors, last 14 days
- Nutritional resilience-18
- GI instability+16
- Inflammatory activity+11
- Toxicity+11
- Treatment adherence+2
What helped?
- Dietary Support Protocol NP-02Day 47Result: symptom burden −20%
- GI Support Protocol GI-04Day 74Result: symptom burden −34%
LIFE OS recommendation
Monitoring Escalation ME-01
91%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable29 min
worsening · -7.9 vs previous 14 d
Sleep duration
Wearable5.6 h
worsening · -0.3 vs previous 14 d
Energy level
Daily log2.2/10
worsening · -1.3 vs previous 14 d
Steps
Wearable3,243
worsening · -562 vs previous 14 d
GI burden
Companion63.9/100
worsening · +15.4 vs previous 14 d
Adherence
Companion49.3 %
worsening · -5.9 vs previous 14 d
Sleep quality
Wearable16/100
worsening · -7.7 vs previous 14 d
Glucose, CGM daily mean
CGM143 mg/dL
stable · +3.7 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 22 from the failing basin, 69 from restoration.
Would help
- ME-01 Monitoring Escalation100% improved among 42 similar · onset 3 d · confidence 79%
- SC-12 Supportive Compound69% improved among 26 similar · onset 6 d · confidence 79%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 79%
- More proteinGI -4.2 next day on high-intake days · n 22
Would not help
- Keep fat lowGI +3.9 next day on high-intake days · n 13
- Keep ultra-processed lowGI +3.3 next day on high-intake days · n 21
- Keep fibre lowGI +2.2 next day on high-intake days · n 16
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4.2supporter · 95%
- Dietary fat load+3.9detractor · 95%
- Ultra-processed food+3.3detractor · 95%
- Insoluble fibre+2.2detractor · 71%
- Simple carbohydrates+1.9detractor · 62%
- Caffeine-1.7no signal · 55%
- Alcohol+1.4no signal · 39%
- Histamine load-0.7no signal · 20%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 59
- WearableHRV 21 ms, trending down
- Autonomic recovery ↓65
- WearableResting HR 83 bpm
- Wearable3,243 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 64 and rising
- WearableSleep 5.6 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 41/100
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑20
- BloodToxicity index 53
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.3 · butyrate capacity 41/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 26 ms
- Sleep
- 6.0 h
- Steps
- 3,767
- Resting HR
- 81 bpm
Daily log: GI score 64, nutritional resilience 31, adherence 49.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02093 | 20% | S05 | AD-05 | no change | 40 |
| P-02483 | 22% | S06 | BR-03 | no change | 64 |
| P-02087 | 21% | S01 | BR-03 | no change | 40 |
| P-02308 | 20% | S13 | BR-03 | no change | 27 |
| P-02151 | 32% | S04 | CR-01 | improved | 49 |
| P-02009 | 30% | S08 | CR-01 | improved | 64 |
| P-02054 | 30% | S01 | CR-01 | improved | 57 |
| P-02025 | 28% | S15 | CR-01 | improved | 61 |
| P-02154 | 27% | S16 | CR-01 | improved | 57 |
| P-02233 | 27% | S16 | CR-01 | improved | 66 |
| P-02274 | 21% | S15 | DT-01 | improved | 50 |
| P-02339 | 21% | S03 | DT-01 | improved | 50 |